Your browser doesn't support javascript.
loading
The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis.
Gómez-Fernández, Paloma; Lopez de Lapuente Portilla, Aitzkoa; Astobiza, Ianire; Mena, Jorge; Urtasun, Andoni; Altmann, Vivian; Matesanz, Fuencisla; Otaegui, David; Urcelay, Elena; Antigüedad, Alfredo; Malhotra, Sunny; Montalban, Xavier; Castillo-Triviño, Tamara; Espino-Paisán, Laura; Aktas, Orhan; Buttmann, Mathias; Chan, Andrew; Fontaine, Bertrand; Gourraud, Pierre-Antoine; Hecker, Michael; Hoffjan, Sabine; Kubisch, Christian; Kümpfel, Tania; Luessi, Felix; Zettl, Uwe K; Zipp, Frauke; Alloza, Iraide; Comabella, Manuel; Lill, Christina M; Vandenbroeck, Koen.
Afiliación
  • Gómez-Fernández P; Neurogenomiks Laboratory, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Lopez de Lapuente Portilla A; Neurogenomiks Laboratory, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Astobiza I; Department of Laboratory Medicine, Lund University, SE-221 00 Lund, Sweden.
  • Mena J; Neurogenomiks Laboratory, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Urtasun A; Neurogenomiks Laboratory, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Altmann V; Inflammation & Biomarkers Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
  • Matesanz F; Neurogenomiks Laboratory, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Otaegui D; Genetic and Molecular Epidemiology Group, Lübeck Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, 23552 Lübeck, Germany.
  • Urcelay E; Department of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, 18002 Granada, Spain.
  • Antigüedad A; Multiple Sclerosis Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, 20014 San Sebastián, Spain.
  • Malhotra S; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, 28014 Madrid, Spain.
  • Montalban X; Department of Neurology, Cruces Hospital, S/N, 48903 Barakaldo, Spain.
  • Castillo-Triviño T; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08007 Barcelona, Spain.
  • Espino-Paisán L; Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08007 Barcelona, Spain.
  • Aktas O; Multiple Sclerosis Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, 20014 San Sebastián, Spain.
  • Buttmann M; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, 28014 Madrid, Spain.
  • Chan A; Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.
  • Fontaine B; Department of Neurology, University of Wuerzburg, 97080 Wuerzburg, Germany.
  • Gourraud PA; Department of Neurology, Caritas Hospital, 97980 Bad Mergentheim, Germany.
  • Hecker M; Department of Neurology, Inselspital Bern, Bern University Hospital, University of Bern, 3011 Bern, Switzerland.
  • Hoffjan S; INSERM, Sorbonne University, Assistance Publique-Hopitaux de Paris (AP-HP), UMR 974 and Neuro-Myology Service, University Hospital Pitié-Salpêtrière, 75013 Paris, France.
  • Kubisch C; Nantes Université, CHU, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ATIP-Avenir, Equipe 5, 44093 Nantes, France.
  • Kümpfel T; CHU de Nantes, INSERM, CIC 1413, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, 44000 Nantes, France.
  • Luessi F; Department of Neurology, Neuroimmunological Section, University of Rostock, 18147 Rostock, Germany.
  • Zettl UK; Department of Human Genetics, Ruhr-University Bochum, 44801 Bochum, Germany.
  • Zipp F; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Alloza I; Institute of Clinical Neuroimmunology, Ludwig-Maximilians University, 80333 Munich, Germany.
  • Comabella M; Department of Neurology, Focus Program Translational Neuroscience, University Medical Center of the Johannes Gutenberg University Mainz, 55116 Mainz, Germany.
  • Lill CM; Department of Neurology, Neuroimmunological Section, University of Rostock, 18147 Rostock, Germany.
  • Vandenbroeck K; Department of Neurology, Focus Program Translational Neuroscience, University Medical Center of the Johannes Gutenberg University Mainz, 55116 Mainz, Germany.
Cells ; 9(1)2020 01 10.
Article en En | MEDLINE | ID: mdl-31936765
The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3). Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in the full dataset (p = 3.17 × 10-4). Importantly, logistic regression analyses conditioning on the main known MS-associated SNP at this locus, rs17066096, revealed that this association was independent from the primary association signal in the full case-control dataset. In silico analysis predicted both disruption of the alpha helix of the H-region of the SP and decreased hydrophobicity of this region, ultimately affecting the SP cleavage site. We tested the effect of the p.Leu16Pro variant on the secretion of IL-22BPi1, IL-22BPi2 and IL-22BPi3 and observed that the Pro16 risk allele significantly lowers secretion levels of each of the isoforms to around 50%-60% in comparison to the Leu16 reference allele. Thus, our study suggests that genetically coded decreased levels of IL-22BP isoforms are associated with augmented risk for MS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Señales de Clasificación de Proteína / Receptores de Interleucina / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Esclerosis Múltiple Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans / Middle aged Idioma: En Revista: Cells Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Señales de Clasificación de Proteína / Receptores de Interleucina / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Esclerosis Múltiple Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans / Middle aged Idioma: En Revista: Cells Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza